22 December 2005
Prevention of motion sickness with rizatriptan: a double-blind, placebo-controlled pilot studyDawn A. Marcus, Joseph M. Furman
Med Sci Monit 2006; 12(1): PI1-7 :: ID: 443201
Background: Serotonergic triptan medications effectively reverse pain andassociated symptoms of migraine. Vestibular symptoms, including dizziness and vertigo, occur in aboutone-third of migraineurs. The most frequent and consistent balance symptom in migraineurs is motion sickness,which is experienced by about half of migraineurs and may be related to serotonergic influences. Thisdouble-blind, placebo-controlled, crossover pilot study was designed to test the hypothesis that pre-treatmentwith the serotonin agonist rizatriptan would prevent motion sickness provocation in headache-free migraineurs.Material/Methods: Ten healthy adult migraineurs (5 migrainous vertigo and 5 migraine without associatedvestibular symptoms) with a history of motion sickness were tested in three sessions: a baseline vestibularbattery and two motion sickness provocation sessions two hours following randomly ordered blinded pre-treatmentwith either oral rizatriptan 10 mg or placebo. Motion sickness was assessed using two standardized questionnaires.Results: Motion sickness scores were lower following pre-treatment with rizatriptan compared with placeboin subjects with migrainous vertigo. Rizatriptan did not affect motion sickness in migraineurs withoutvertigo. Otolith-ocular reflex sensitivity was reduced following pretreatment with rizatriptan in bothgroups. Conclusions: This is the first study in humans testing a triptan serotonin agonist as a preventivetool for motion sickness. Rizatriptan prevented the development of motion sickness and severe motionsickness symptoms in patients with migrainous vertigo. These pilot data suggest a possible role for serotoninin the development of motion sickness symptoms in migraineurs with migrainous vertigo.
Keywords: Cross-Over Studies, Double-Blind Method, Migraine Disorders - drug therapy, Motion Sickness - physiopathology, Placebos, Serotonin Receptor Agonists - therapeutic use, Triazoles - therapeutic use, Tryptamines - therapeutic use
01 June 2023 : EditorialEditorial: Infectious Disease Surveillance Using Artificial Intelligence (AI) and its Role in Epidemic and Pandemic Preparedness
Med Sci Monit 2023; 29:e941209
08 Jun 2023 : Clinical ResearchRisk Factors for New Vertebral Compression Fracture After Percutaneous Vertebral Augmentation: A Retrospect...
Med Sci Monit In Press; DOI: 10.12659/MSM.940134
08 Jun 2023 : Clinical ResearchA Nomogram for Identifying HR+/Her2- Breast Cancer Patients with Positive Sentinel Lymph Nodes and Omitted ...
Med Sci Monit In Press; DOI: 10.12659/MSM.940124
08 Jun 2023 : Clinical ResearchBurden of COVID-19 on Mental Health of Resident Doctors in Poland
Med Sci Monit In Press; DOI: 10.12659/MSM.940208
08 Jun 2023 : Clinical ResearchRisk Prediction for Rapidly Progressive Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis: Th...
Med Sci Monit In Press; DOI: 10.12659/MSM.940251
Most Viewed Current Articles
13 Nov 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292
01 Jan 2022 : EditorialEditorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...
Med Sci Monit 2022; 28:e935952